Bromodomain Testis Specific Protein - Drugs In Development, 2021

June 2021 | 69 pages | ID: B4D6C8FFB709EN
Global Markets Direct

Abstracts

Bromodomain Testis Specific Protein - Drugs In Development, 2021

SUMMARY

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) pipeline Target constitutes close to 5 molecules. The latest report Bromodomain Testis Specific Protein - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Bromodomain testis-specific protein is a protein encoded by the BRDT gene. It plays a role in meiotic and post-meiotic cells by binding to acetylated histones at the promoter of specific meiotic and post-meiotic genes, facilitating their activation at the appropriate time. It binds to hyperacetylated histones and participates in their general removal from DNA. The molecules developed by companies in Phase III, Phase II and Phase I stages are 1, 1 and 3 respectively.

Report covers products from therapy areas Oncology which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Solid Tumor, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Ovarian Cancer, Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Colorectal Cancer, Epithelial Ovarian Cancer, Follicular Lymphoma, Lung Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Myelofibrosis, Myeloproliferative Disorders, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Mediastinal B-Cell Lymphoma, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Unspecified B-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT)
• The report reviews Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics and enlists all their major and minor projects
• The report assesses Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Overview
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Companies Involved in Therapeutics Development
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Constellation Pharmaceuticals Inc
Ningbo Wenda Pharmaceutical Technology Co Ltd
Zenith Epigenetics Ltd
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Drug Profiles
BI-894999 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-95775 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NHWD-870 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pelabresib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEN-3694 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Dormant Products
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Discontinued Products
Bromodomain Testis Specific Protein (Cancer/Testis Antigen 9 or RING3 Like Protein or BRDT) - Product Development Milestones
Featured News & Press Releases
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib
Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib
Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combination of ZEN-3694 + Merck’s immune check point inhibitor KEYTRUDA
Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer
Dec 06, 2020: Constellation Pharmaceuticals provides update of MANIFEST study for CPI-0610 at ASH Meeting
Nov 23, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610 presented at ASH Meeting
Jul 29, 2020: Zenith Epigenetics advances ZEN-3694 in multiple cancer programs
Jul 29, 2020: Researchers optimistic after dose-determining trial of compound against metastatic castration-resistant prostate cancer
Jun 12, 2020: Constellation Pharmaceuticals provides updates of MANIFEST study for CPI-0610 and EZH2 Franchise
May 28, 2020: Constellation Pharmaceuticals to host analyst/investor event to discuss update of MANIFEST clinical trial for CPI-0610
May 28, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610
May 14, 2020: Constellation Pharmaceuticals provides update of preliminary data for CPI-0610 in three EHA Abstracts
Apr 15, 2020: New cancer drug shrinks tumors, reduces side effects, in animal studies
Jan 07, 2020: Zenith Epigenetics receives US$5 million milestone payment from Newsoara
Dec 19, 2019: Zenith Epigenetics announces clinical advancement of ZEN-3694
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Boehringer Ingelheim International GmbH, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Constellation Pharmaceuticals Inc, 2021
Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2021
Pipeline by Zenith Epigenetics Ltd, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021